Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses

Melmed, Gil Y.; Ippoliti, Andrew F.; Papadakis, Konstantinos A.; Tran, Tram T.; Birt, Jaime L.; Lee, Susie K.; Frenck, Robert W.; Targan, Stephan R.; Vasiliauskas, Eric A.
August 2006
American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1834
Academic Journal
BACKGROUND: Patients with chronic, immune-mediated conditions such as inflammatory bowel disease (IBD) are often treated with long-term immunosuppressive therapies, potentially increasing their risk of developing an infection. Empiric data suggest that vaccines are underutilized in immunocompromised patients, despite published guidelines recommending their use. We aimed to assess exposure risk and immunization status among patients receiving care in an IBD specialty clinic. METHODS: Patients completed a self-administered, pretested, structured questionnaire during a routine visit for the management of IBD. Survey questions related to medical and immunization histories, and exposures to known risk factors for influenza, pneumococcus, viral hepatitis, and varicella. Additionally, in a subgroup of patients who agreed to donate a sample of blood, immune status to hepatitis A (HAV), hepatitis B (HBV), and varicella was determined. RESULTS: Two hundred four patients were asked to participate in the study; 169 completed surveys and comprised the study population. Mean age was 35 yr (range 13–75 yr). One hundred forty-six respondents (86%) reported current or prior use of immunosuppressive medications. Only 45% of respondents recalled tetanus immunization within the past 10 yr, 41 (28%) reported regularly receiving flu shots, and 13 (9%) reported having received pneumococcal vaccine. The most common reasons for nonimmunization with influenza included lack of awareness (49%) and concern for side effects (18%). Responses indicated that 75 (44%) patients were at risk for HBV but only 47 (28%) had been vaccinated against the infection; of patients with previous HBV vaccination, only three of nine (33%) had measurable antibodies against hepatitis B surface antigen. CONCLUSIONS: Immunization against selected vaccine-preventable illnesses was uncommon in patients with IBD, despite the presence of significant risk factors. Efforts to improve immunization status among patients with IBD and other chronic, immune-mediated conditions are needed.


Related Articles

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...

  • Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. R K Weersma // Gut;Mar2009, Vol. 58 Issue 3, p388 

    BACKGROUND: Crohn’s disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD). METHODS: We studied 2804...

  • Inflammatory Bowel Disorders.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p21 

    The article discusses various research that explored the different aspects of inflammatory bowel disorders. One of the studies dealt with the changes in surgical resection rates and medical treatments for Crohn's disease. Another research focused on the association of pre-operative management...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. Mikocka-Walus, Antonina A; Turnbull, Deborah A; Moulding, Nicole T; Wilson, Ian G; Andrews, Jane M; Holtmann, Gerald J // BMC Gastroenterology;2007, Vol. 7, p38 

    Background: Interest in psychological factors in patients with inflammatory bowel disease (IBD) has increased in recent years. It has even been proposed that treating psychological co-morbidities with antidepressants may control disease activity and improve quality of life. Despite this, there...

  • Relationship between the polymorphism of tumor necrosis factor-α-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Wang Fan; Wang Maoqing; Chen Wangyang; Hu Fulan; Li Dandan; Ren Jiaojiao; Dong Xinshu; Cui Binbin; Zhao Yashuang // European Journal of Human Genetics;Apr2011, Vol. 19 Issue 4, p432 

    Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are common health problems worldwide. Tumor necrosis factor (TNF) is a type of cytokine that induces inflammation and inhibits tumorigenesis. Several studies have assessed the relationship between the polymorphism of TNF-α-308 G>A...

  • Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. Ananthakrishnan, Ashwin N.; McGinley, Emily L.; Binion, David G. // American Journal of Gastroenterology;Nov2008, Vol. 103 Issue 11, p2789 

    OBJECTIVE: To examine if a high hospital volume was associated with superior outcomes in inflammatory bowel disease (IBD) patients requiring hospitalization. METHODS: This was a cross-sectional study using data from the Nationwide Inpatient Sample (NIS 2004). IBD-related hospitalizations were...

  • Role of Procalcitonin in Infectious Gastroenteritis and Inflammatory Bowel Disease. Kelvin Thia; Edwin Chan; Khoon-Lin Ling; Wai-Yoong Ng; Edward Jacob; Choon-Jin Ooi // Digestive Diseases & Sciences;Nov2008, Vol. 53 Issue 11, p2960 

    Abstract   Background and Aim We have evaluated procalcitonin (PCT) as a diagnostic marker for bacterial gastroenteritis (GE) and as a disease activity marker in inflammatory bowel disease (IBD) patients. Methods This was a prospective single-center study performed over a 1-year...

  • Five Cases of De Novo Inflammatory Bowel Disease After Orthotopic Liver Transplantation. Wörns, Marcus A.; Lohse, Ansgar W.; Neurath, Markus F.; Croxford, Andrew; Otto, Gerd; Kreft, Andreas; Galle, Peter R.; Kanzler, Stephan // American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1931 

    Immunosuppression is currently the treatment of choice for severe inflammatory bowel disease (IBD). Thus, it was anticipated that the course of preexisting IBD should improve after orthotopic liver transplantation (OLT). Despite sufficient allograft immunosuppressive therapy, however,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics